Compositions for alleviating inflammation and oxidative stress in a mammal
An antioxidant-promoting composition that increases antioxidant defense potential in a subject is disclosed comprising Bacopa monniera extract; milk thistle extract, ashwagandha powder, green tea extract, Gotu kola powder, Ginko biloba leaf extract; Aloe vera powder; turmeric extract; and N-acetyl cysteine. The antioxidant-promoting composition of the invention safely induces cellular antioxidant potential to achieve an overall net decrease in oxidative stress without the undesirable side-effects associated with the individual components of the antioxidant-promoting composition. Also disclosed is a method for reducing the undesirable side-effects of free radicals in a subject by administering to a subject in need of such antioxidants an effective amount of antioxidant-promoting composition of the invention.
1. A composition comprising: (a) at least about 150 milligrams Bacopa monniera extract, wherein said Bacopa monniera extract is comprised of 45 percent bacosides; at least about 225 milligrams silybum marianum (milk thistle) extract, wherein said milk thistle extract is comprised of between about 70 percent and about 80 percent silymarin; at least about 150 mg Withania somnifera (ashwagandha) powder; at least about 75 milligrams Camellia sinensis (green tea extract); wherein said green tea extract is comprised of 98 percent polyphenols; said polyphenols comprised of 45 percent (−)-epigallocatechin gallate; at least about 75 milligrams Curcuma longa (turmeric) extract; wherein said turmeric extract is comprised of 95 percent curcumin; wherein the composition increases the enzyme activity level of at least one antioxidant enzyme selected from the group consisting of: superoxide dismutase and catalase and decreases the plasma concentration level of thiobarbituric acid reactive chemical species, when administered in an effective amount to a mammalian subject in need thereof.
2. The composition according to claim 1 , wherein the composition is formulated as an oral dosage form.
3. The composition according to claim 2 , wherein the oral dosage form is selected from the group consisting of: a tablet; capsule; and caplet.